Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal

(Reuters) - Japan's Takeda Pharmaceutical Co Ltd said on Monday it would buy cancer drug maker Ariad Pharmaceuticals Inc in a deal valued at $5.20 billion, to beef up its oncology pipeline.

Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal
Read More


Bagikan Berita Ini